Loading
companiesCompany
Coherus BioSciences
Coherus is a Californian company that grew up on biosimilars and now holds the US rights to toripalimab, the anti-PD-1 antibody approved in 2023 for nasopharyngeal carcinoma, the first FDA approval for that cancer.
Also called: Coherus BioSciences, Inc.Coherus Oncology
Overview
Coherus BioSciences, based in Redwood City, California, built its business on biosimilars of pegfilgrastim and other biologics before refocusing on oncology. It licensed the anti-PD-1 antibody toripalimab from Junshi Biosciences for the United States and Canada and won FDA approval in October 2023 for recurrent or metastatic nasopharyngeal carcinoma with chemotherapy, the first drug approved in the United States for that disease. The company is developing toripalimab combinations and other immuno-oncology candidates. Company facts are from the official website and FDA approval records.
Headquarters
Redwood City, CA, US
Scorecard
All companies#123of 1244 companies, score 45
- approved products +6
- targets +2
- modalities +2
- regions +5
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 1 targets, 548 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
ApprovedMonoclonal antibody (anti-PD-1)
Toripalimab · Loqtorzi
A Chinese-developed PD-1 blocker that became the first immunotherapy approved in the US for nasopharyngeal cancer.
Similar pages
- CompanyMerck KGaA (EMD Serono)
Shares Head and neck squamous cell carcinoma and the tag fda-oce-applicant.
- Key paperJUPITER-02: toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma
Shares JUPITER-02, Toripalimab.
- PersonJun Ma
- TrialCAPTAIN-1st
- TrialKC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
Shares Toripalimab, Oesophageal cancer.
- PersonLi Zhang
- TrialJUPITER-06
Shares Toripalimab, Oesophageal cancer.
- TrialA Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
cancers
fronts
drugs
ApprovedMonoclonal antibody (anti-PD-1)
Toripalimab · Loqtorzi
trials
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRCImmunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon CancerJUPITER-02Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver MetastasesSTC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas